Memantine for the Prevention of Cognitive Dysfunction and Negative Symptoms in Patients With Acute Schizophrenia

NCT00148590 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: Memantine
DRUG: Placebo

Sponsor

M. Schaefer, MD

Collaborators

[object Object]